The world's biggest makers of insulin are likely to make more money, not less, even after slashing prices by as much as 75% due to US government pressure.
That's because Novo Nordisk announced price cuts to their insulin products on Tuesday, less than two weeks after rival Eli Lilly & Co. announced its own price cuts. However, both companies could avoid paying out multimillion-dollar rebates to the government's Medicaid health-care program.
A 2021 law incentivized the companies to lower prices by removing a cap on the rebate payment, a change that kicks in next year. Federal and state governments claim the rebates from drugmakers to help offset the cost of covering prescription drugs under government programs.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.